Literature DB >> 29036880

Correction: Zhang, G.; Cheng, G.; Jia, P.; Jiao, S.; Feng, C.; Hu, T.; Liu, H.; Du, Y. The Positive Correlation of the Enhanced Immune Response to PCV2 Subunit Vaccine by Conjugation of Chitosan Oligosaccharide with the Deacetylation Degree. Marine Drugs 2017, 15, 236.

Guiqiang Zhang1,2, Gong Cheng3, Peiyuan Jia4, Siming Jiao5, Cui Feng6, Tao Hu7, Hongtao Liu8, Yuguang Du9.   

Abstract

The authors wish to correct Figure 1 in this paper [1] to be as follows:[...].

Entities:  

Year:  2017        PMID: 29036880      PMCID: PMC5618431          DOI: 10.3390/md15090292

Source DB:  PubMed          Journal:  Mar Drugs        ISSN: 1660-3397            Impact factor:   5.118


The authors wish to correct Figure 1 in this paper [1] to be as follows:
Figure 1

Reaction scheme of the chitosan oligosaccharides–porcine circovirus type 2 (COS-PCV2) conjugate synthesis.

The authors wish to correct the order of references 9 and 10 in References Part of [1] to be as follows: Wang, Z.; Zheng, L.; Yang, S.; Niu, R.; Chu, E.; Lin, X. N-acetylchitooligosaccharide is a potent angiogenic inhibitor both in vivo and in vitro. Biochem. Biophys. Res. Commun. 2007, 357, 26–31. Wu, H.; Aam, B.B.; Wang, W.; Norberg, A.L.; Sørlie, M.; Eijsink, V.G.; Du, Y. Inhibition of angiogenesis by chitooligosaccharides with specific degrees of acetylation and polymerization. Carbohydr. Polym. 2012, 89, 511–518.
  1 in total

1.  The Positive Correlation of the Enhanced Immune Response to PCV2 Subunit Vaccine by Conjugation of Chitosan Oligosaccharide with the Deacetylation Degree.

Authors:  Guiqiang Zhang; Gong Cheng; Peiyuan Jia; Siming Jiao; Cui Feng; Tao Hu; Hongtao Liu; Yuguang Du
Journal:  Mar Drugs       Date:  2017-07-26       Impact factor: 5.118

  1 in total
  1 in total

Review 1.  Porcine Circovirus Type 2 Vaccines: Commercial Application and Research Advances.

Authors:  Jinshuo Guo; Lei Hou; Jianwei Zhou; Dedong Wang; Yongqiu Cui; Xufei Feng; Jue Liu
Journal:  Viruses       Date:  2022-09-10       Impact factor: 5.818

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.